

BRAF-Mutant Metastatic Melanoma- Pipeline Insight, 2020

<https://marketpublishers.com/r/B529BA3CC4C0EN.html>

Date: February 2020

Pages: 106

Price: US\$ 1,500.00 (Single User License)

ID: B529BA3CC4C0EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

BRAF-Mutant Metastatic Melanoma Overview

' BRAF-Mutant Metastatic Melanoma Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The BRAF-Mutant Metastatic Melanoma Market. A Detailed Picture Of The BRAF-Mutant Metastatic Melanoma Pipeline Landscape Is Provided, Which Includes The Disease Overview And BRAF-Mutant Metastatic Melanoma Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth BRAF-Mutant Metastatic Melanoma Commercial Assessment And Clinical Assessment Of The BRAF-Mutant Metastatic Melanoma Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, BRAF-Mutant Metastatic Melanoma Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.

BRAF-Mutant Metastatic Melanoma Of Pipeline Development Activities

The Report Provides Insights Into:

All Of The Companies That Are Developing Therapies For The Treatment Of BRAF-Mutant Metastatic Melanoma With Aggregate Therapies Developed By

Each Company For The Same.

Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The BRAF-Mutant Metastatic Melanoma Treatment.

BRAF-Mutant Metastatic Melanoma Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.

Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.

Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of BRAF-Mutant Metastatic Melanoma Market.

The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

BRAF-Mutant Metastatic Melanoma Analytical Perspective By DelveInsight

In-Depth BRAF-Mutant Metastatic Melanoma Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

BRAF-Mutant Metastatic Melanoma Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

SCOPE OF THE REPORT

The BRAF-Mutant Metastatic Melanoma Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For BRAF-Mutant Metastatic Melanoma Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.

It Comprises Of Detailed Profiles Of BRAF-Mutant Metastatic Melanoma Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details

Detailed BRAF-Mutant Metastatic Melanoma Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.

Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across BRAF-Mutant Metastatic Melanoma.

REPORT HIGHLIGHTS

A Better Understanding Of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For BRAF-Mutant Metastatic Melanoma.

In The Coming Years, The BRAF-Mutant Metastatic Melanoma Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.

The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence BRAF-Mutant Metastatic Melanoma R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.

A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The BRAF-Mutant Metastatic Melanoma Treatment Market. Several Potential Therapies For BRAF-Mutant Metastatic Melanoma Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The BRAF-Mutant Metastatic Melanoma Market Size In The Coming Years.

Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of BRAF-Mutant Metastatic Melanoma) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

KEY QUESTIONS

What Are The Current Options For BRAF-Mutant Metastatic Melanoma Treatment?

How Many Companies Are Developing Therapies For The Treatment Of BRAF-Mutant Metastatic Melanoma?

What Are The Principal Therapies Developed By These Companies In The Industry?

How Many Therapies Are Developed By Each Company For The Treatment Of BRAF-Mutant Metastatic Melanoma?

How Many BRAF-Mutant Metastatic Melanoma Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of BRAF-Mutant Metastatic Melanoma?

Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?

What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact BRAF-

Mutant Metastatic Melanoma Market?

Which Are The Dormant And Discontinued Products And The Reasons For The Same?

What Is The Unmet Need For Current Therapies For The Treatment Of BRAF-Mutant Metastatic Melanoma?

What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing BRAF-Mutant Metastatic Melanoma Therapies?

What Are The Clinical Studies Going On For BRAF-Mutant Metastatic Melanoma And Their Status?

What Are The Results Of The Clinical Studies And Their Safety And Efficacy?

What Are The Key Designations That Have Been Granted For The Emerging Therapies For BRAF-Mutant Metastatic Melanoma?

How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of BRAF-Mutant Metastatic Melanoma?

Contents

1. REPORT INTRODUCTION

2. BRAF-MUTANT METASTATIC MELANOMA

- 2.1. Overview
- 2.2. History
- 2.3. BRAF-Mutant Metastatic Melanoma Symptoms
- 2.4. Causes
- 2.5. Pathophysiology
- 2.6. BRAF-Mutant Metastatic Melanoma Diagnosis
 - 2.6.1. Diagnostic Guidelines

3. BRAF-MUTANT METASTATIC MELANOMA CURRENT TREATMENT PATTERNS

- 3.1. BRAF-Mutant Metastatic Melanoma Treatment Guidelines

4. BRAF-MUTANT METASTATIC MELANOMA - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
 - 4.1.1. BRAF-Mutant Metastatic Melanoma companies collaborations, Licensing, Acquisition -Deal Value Trends
 - 4.1.1.1. Assessment Summary
 - 4.1.2. BRAF-Mutant Metastatic Melanoma Collaboration Deals
 - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.3. BRAF-Mutant Metastatic Melanoma Acquisition Analysis

5. THERAPEUTIC ASSESSMENT

- 5.1. Clinical Assessment of Pipeline Drugs
 - 5.1.1. Assessment by Phase of Development
 - 5.1.2. Assessment by Product Type (Mono / Combination)
 - 5.1.2.1. Assessment by Stage and Product Type
 - 5.1.3. Assessment by Route of Administration
 - 5.1.3.1. Assessment by Stage and Route of Administration
 - 5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. BRAF-MUTANT METASTATIC MELANOMA LATE STAGE PRODUCTS (PHASE-III)

7. BRAF-MUTANT METASTATIC MELANOMA MID STAGE PRODUCTS (PHASE-II)

8. EARLY STAGE PRODUCTS (PHASE-I)

9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS

10. INACTIVE PRODUCTS

11. DORMANT PRODUCTS

12. BRAF-MUTANT METASTATIC MELANOMA DISCONTINUED PRODUCTS

13. BRAF-MUTANT METASTATIC MELANOMA PRODUCT PROFILES

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report?

14. BRAF-MUTANT METASTATIC MELANOMA KEY COMPANIES

15. BRAF-MUTANT METASTATIC MELANOMA KEY PRODUCTS

16. DORMANT AND DISCONTINUED PRODUCTS

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. BRAF-MUTANT METASTATIC MELANOMA UNMET NEEDS

18. BRAF-MUTANT METASTATIC MELANOMA FUTURE PERSPECTIVES

19. BRAF-MUTANT METASTATIC MELANOMA ANALYST REVIEW

20. APPENDIX

21. REPORT METHODOLOGY

21.1. Secondary Research

21.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1: BRAF-Mutant Metastatic Melanoma Diagnostic Guidelines
- Table 2: BRAF-Mutant Metastatic Melanoma Treatment Guidelines
- Table 3: Assessment Summary
- Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5: BRAF-Mutant Metastatic Melanoma Acquisition Analysis
- Table 6: Assessment by Phase of Development
- Table 7: Assessment by Product Type (Mono / Combination)
- Table 8: Assessment by Stage and Product Type
- Table 9: Assessment by Route of Administration
- Table 10: Assessment by Stage and Route of Administration
- Table 11: Assessment by Molecule Type
- Table 12: Assessment by Stage and Molecule Type
- Table 13: Assessment by MOA
- Table 14: Assessment by Stage and MOA
- Table 15: Assessment by Target
- Table 16: Assessment by Stage and Target
- Table 17: BRAF-Mutant Metastatic Melanoma Late Stage Products (Phase-III)
- Table 18: BRAF-Mutant Metastatic Melanoma Mid Stage Products (Phase-II)
- Table 19: BRAF-Mutant Metastatic Melanoma Early Stage Products (Phase-I)
- Table 20: Pre-clinical and Discovery Stage Products
- Table 21: Inactive Products
- Table 22: Dormant Products
- Table 23: Discontinued Products

List Of Figures

LIST OF FIGURES

Figure 1: Disease Overview

Figure 2: History

Figure 3: Symptoms

Figure 4: Causes

Figure 5: Pathophysiology

Figure 6: Diagnostic Guidelines

Figure 7: Treatment Guidelines

Figure 8: BRAF-Mutant Metastatic Melanoma companies collaborations, Licensing, Acquisition -Deal Value Trends

Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis

Figure 10: BRAF-Mutant Metastatic Melanoma Acquisition Analysis

Figure 11: Assessment by Phase of Development

Figure 12: Assessment by Product Type (Mono / Combination)

Figure 13: Assessment by Stage and Product Type

Figure 14: Assessment by Route of Administration

Figure 15: Assessment by Stage and Route of Administration

Figure 16: Assessment by Molecule Type

Figure 17: Assessment by Stage and Molecule Type

Figure 18: Assessment by MOA

Figure 19: Assessment by Stage and MOA

Figure 20: Late Stage Products (Phase-III)

Figure 21: Mid Stage Products (Phase-II)

Figure 22: Early Stage Products (Phase-I)

Figure 23: Pre-clinical and Discovery Stage Products

Figure 24: Inactive Products

Figure 25: Dormant Products

Figure 26: Discontinued Products

Figure 27: Unmet Needs

I would like to order

Product name: BRAF-Mutant Metastatic Melanoma- Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/B529BA3CC4C0EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B529BA3CC4C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970